

Author: Naik S.S.
Publisher: Adis International
ISSN: 1170-7690
Source: PharmacoEconomics, Vol.13, Iss.6, 1998-06, pp. : 677-686
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
In the absence of evidence in the literature on cost factors in the management of leprosy, a reference is made to the sporadic attempts to study costs of case detection and treatment. Such studies indicate that in the currently declining phase of leprosy endemicity, employing a conventionally trained, salaried class of paramedical staff for field surveys is prohibitively expensive if cost per case detected is computed. Involving primary healthcare and community derived workers is cost effective. Likewise, short course chemotherapy with newer drugs under trial, administered under supervision by community volunteers, reduces the expenses considerably. Community-based disability services using inexpensive tools may cut costs by 90%. Operational research on cost effectiveness of rehabilitation comparing integrated with vertical approaches is, unfortunately, still in a primitive stage.It is urged that in view of the changing logistics, manpower costs and financial implications should be given serious consideration by health planners. Post-elimination problems such as:
Integration of leprosy into general healthcare services and community-based rehabilitation of leprosy patients along with those disabled by other diseases will be the major task in future as these procedures are expected to reduce management costs and eliminate stigma.
Related content


By Volmer T.
Pulmonary Pharmacology & Therapeutics, Vol. 14, Iss. 1, 2001-01 ,pp. :


PharmacoEconomics and Outcomes News, Vol. 1, Iss. 520, 2007-01 ,pp. :


WHO global drug safety programme admits 100th member
Reactions Weekly, Vol. 1, Iss. 1323, 2010-01 ,pp. :




Infliximab: Leprosy: case report
Reactions Weekly, Vol. 1, Iss. 1372, 2011-01 ,pp. :